The study — which was led by Rutgers Cancer Institute of New Jersey in New Brunswick — is to feature at the 2018 annual meeting of the American Association for Cancer Research, which will be held in Chicago, IL.
This study is not the first to suggest metformin as a potential treatment for pancreatic cancer, but it is the first to show that the underlying mechanism involves the drug’s effect on the REarranged during Transfection (RET) cell signaling pathway.
Kent: Hi, my name’s Kent Rhodes and I have a Grade 4 Glioblastoma, and I was first diagnosed on the 27th of September 2016. After the initial, I suppose shock would be a good word, I visited Care Oncology on the 14th of October 2016, and met the wonderful Ndaba who told me how we were going to save my life. And the rest, as they say, is history. At the moment we are doing very well.
Ndaba: Well, thank you very much, Kent. What led you to seek additional options for treatment?0
Kent: Well, a very simple philosophy … first of all, I’m a business coach and it’s all about positive mindset, so the first thing is always focus on what you can do, not on what you can’t do. And another thing that I always preach to my clients is hope is not a strategy. So, you’ve got to be positive, but you’ve got to go and look at what can I do? I obviously looked at what the NHS could provide, but the prognosis I was told I would be guaranteed to not make it, and that I’m looking at 18 to 24 months of life. That just wasn’t an option for me, so I’ve got to find somebody that’s got the best results and copy what they do, which is exactly what I do with business ideas. Get them to follow recipes that were successful.
See long term Glioblastoma survivors in the news who use the COC Protocol:
Care Oncology Clinic was established in October 2014 by SEEK Group. Headquartered in London, SEEK is involved in research and development, sales of over the counter and prescription medicines and management and operation of clinics. It undertakes all these activities in order to bring safe, effective and low cost medicines to patients in the shortest time possible to radically improve human health in major disease areas.
View COC Treatment Process Now by filling out the following form:
Ben Williams is the only gentleman that I’ve found that had actually beaten my type of cancer. So we looked into Ben Williams – to be fair it wasn’t me. One of my very dear friends, Robin Graham, who is a homeopath, natural healer, she found Care Oncology based on Ben Williams‘ research. To be honest, I almost didn’t make it to that appointment because I was so overwhelmed and whatever, and if it wasn’t for Robin I don’t think I would have got this. Very, very grateful to have people around me who have supported me.
Invariably, when people are first diagnosed, you’re just overwhelmed. What I found when I got to Care Oncology was, I really felt like I had hope, that there was hope to beat this thing; that there was a strategy, not just hope. Very pleased that I actually made it to that appointment because it was very close that I didn’t.
Ndaba: Very good, thank you. You clearly mention that you found the Care Oncology Clinic helpful in terms of giving you hope, and strategy along with the hope. Are there any other ways in which you think the clinic has been helpful to you?
Kent: Just knowing that I’ve got people supporting me, knowing that I can pick up the phone and ask questions, which I did initially in the beginning I suppose, that was really helpful. Not only Ndaba himself, but the support staff are fantastic. The getting of your prescription, or receiving of it, initially I had a bit of a challenge with that, but we sorted that out really quickly. Raph was really fantastic with that. It’s all a little bit autopilot right now – long may that last – and hoping, because bear in mind hope’s not a strategy, but hoping if we follow the same progression that we’ll be treatment free by the end of the year.
Ndaba: Great, thank you. The clinic, as well as treating people like yourself obviously, is undertaking a research study where there are a lot more people like yourself who are included in evidence gathering. Tell me a bit about what it means to you to be involved in this sort of bigger picture, as well. Is that something that you think about, interests you, or has it mainly been about the focusing on your own treatment? Do you have any thoughts about the bigger picture, which is clearly what the Care Oncology Clinic is also involved in?
Kent: Yes. Now, one of my first priorities is obviously to make sure I survive, but I would really, the fact that I’m doing this, I’d like to be part of helping other people understand what can happen. What makes me really sad is, we have a solution and the general medical field are not prepared to accept it. So, once I’ve beaten this thing as well, I want to write a book; I’m a public speaker by profession. I want to go out and actually make it not about my business, but make it about the awareness of what is possible. Because you’ve got to believe that you can beat it, but it’s a hell of a lot easier when you’ve got people who can show you how to do it.
So, yeah, I will be hugely involved. I’m a bit self-absorbed at the moment, but wherever I can I help people. The further I get in this journey, the more people pick up the phone, they know a friend, they’ve got a family member. So I reckon I’m typically talking to somebody once a week about their cancer journey. I must have sent about 10 people in your direction. Whether or not they actually contacted Care Oncology, I don’t … I just give the option, I put it in front of them so they have choice. But it’s amazing how many people put their head in the sand and they just don’t want to know.
Ndaba: Well, thank you very much. I’m sure you’ll be an amazing, inspiring, and articulate voice.
Kent: I’m planning to do; thank you Ndaba. That’s the aim.
Dr Ndabezinhle Mazibuko
MBBS – Clinical Research Fellow in Clinical Neuroscience (Institute of Psychiatry, Psychology and Neuroscience – King’s College London)
After my devastating diagnosis of Glioblastoma Multiforme, an aggressive and deadly form of brain cancer, I was told that the standard of care treatment would give me a 3% survival rate with a possibility of living for 12-15 months.
I am an active, 48 year old mother and wife, and I am not ready to leave my family and friends. I needed to find some alternative treatments because the standard medical ones were insufficient.
In my frantic and non-stop research, I repeatedly found and read about Care Oncology’s research and findings. Not until a friend in London, who happens to be in the medical field, advised me to do so, did I visit Care Oncology’s website and delve further into COC’s protocol. I was intrigued by their evidence-based approach. As I researched further, I found that the COC’s treatment was having success and garnering accolades from the research and medical community. I wanted to be part of their protocol.
I quickly learned that the Care Oncology Clinic opened an office in the USA. Without hesitation, I scheduled an appointment and flew to South Dakota where their clinic is located. I met with Dr. Larson, an established physician who has a deep understanding of how repurposing drugs may both treat and prevent cancer, and Travis Christofferson, who is on the forefront of alternative treatments to cancer, specifically, the metabolic approach and the repurposing of drug protocols. Both Travis and Dr. Larson have been my sage guides through this process : checking-in on a regular basis, offering suggestions and monitoring my labs. I’m 100% confident that my care is in competent hands.
I feel that COC’s protocol is a no-brainer for my treatment. To fight my cancer, COC prescribes existing, low cost and well tolerated drugs which are repurposed and prescribed using innovative research findings. After a “getting used to” period, I quickly adjusted to the minimal side effects of a couple of the drugs. I have been on COC’s protocol for 7 months, and I am happy to report that my MRI Scans show no sign of a recurrent tumor.
With Care Oncology Clinic’s protocol as a line of defense against the recurrence of my cancer, I am hopeful for my future.
We tend to associate breakthrough treatments with new — and often unaffordable — drugs.
But it seems a remarkable improvement in the survival time of patients with brain cancer has been achieved using a combination of four old drugs (a statin, a diabetes pill, an antibiotic tablet and a dewormer) that cost just £400 a year.
Results from an ongoing trial run by the private Care Oncology Clinic in London suggest that giving this new combination treatment doubled the average survival time.
Read more: http://www.dailymail.co.uk/health/article-5492485/Could-400-year-drug-cocktail-beat-one-deadliest-cancers.html#ixzz59dreUI1c
Follow us: @MailOnline on Twitter | DailyMail on Facebook
Although rare, adrenocortical carcinoma is among the most common tumors found in children with Li-Fraumeni syndrome and Li-Fraumeni-like syndrome, associated with germ-line mutations in the TP53 gene. In southern Brazil, one form of Li-Fraumeni syndrome, associated with childhood adrenocortical carcinoma, is caused by a mutation in the R337H TP53 tetramerisation domain and is attributed to a familial founder effect. Adrenocortical carcinoma is considered an aggressive neoplasm, usually of poor prognosis and is generally unresponsive to systemic chemotherapy. Optimal treatment regimens remain to be established. We report the case of a young woman with metastatic adrenocortical carcinoma, who achieved stable disease with mitotane, cisplatin, doxorubicin, and etoposide as first-line therapy, but then had an objective response to oral metformin that lasted 9 months. The presence of the R337H TP53 mutation suggests a mechanism for the observed response to metformin.
Patient Testimonial – 40 year old female with breast cancer
1) When did you first visit Care Oncology Clinic and commence adjunct treatment? What led you to seek out additional treatment options?
I first visited the COC in September 2016. This was halfway through my chemotherapy treatment for breast cancer.
Despite the intended outcome of my primary cancer treatment to be curative, I was shocked by the number of women I met through support groups who had experienced a return or spread of their breast cancer in the years after completing primary treatment. I then analysed the statistics and profile of my cancer diagnosis – it suggested I also faced this risk. I simply knew I had to do more.
Dr Conte MD from the University of Padova and Istituto Oncologico Veneto, in Padova, Italy, recently stated:
“it is estimated that approximately 30% of patients presenting with non-metastatic breast cancer at the initial diagnosis will eventually relapse following standard treatments and require subsequent treatment”
I decided immediately that 30% of patients is more than just “an unlucky few” for whom primary treatment is unsuccessful. In addition, I had read that many patients acquire resistance to the long-term ongoing hormone treatments which are designed to keep the disease at bay (such as Tamoxifen or aromatase inhibitors). My view was – I’ve had cancer and I’ve been treated however, why should I wait to see if the treatment worked for me and for cancer to progress to an incurable stage? After all, prevention is always better than a cure.
From here I began my own research which quickly revealed that there were indeed additional, well researched drugs that may be beneficial from an “anti-cancer” perspective that had very low toxicity to the body. I was also aware that several books on cancer drug combinations or “cocktail therapy” had been published and had gathered a following. After all, drug combinations were what helped to crack the treatment of HIV… why not cancer?
I began wondering how I could get a GP or oncologist to prescribe some of these off-label drugs when a friend shared a newspaper article about the Care Oncology Clinic. I immediately booked an appointment with them. Maybe the COC treatments could even help make my primary treatment more effective? I signed on as a patient.
My approach to treatment has been about adding in additional drugs, treatments, therapies and supplements that would provide an upside chance against tackling the cancer in my body, whilst having very little downside to my general health. Doing more and being proactive felt a lot better than the sitting duck option.
In summary, what led me to seek out treatment options? Primary cancer treatment doesn’t work for everyone. I am 40 years old with a young family. Whilst I have completed treatment for the cancer diagnosis I had, I want to do everything I can to prevent it returning to or spreading around my body. COC is helping me to do that with off-label drugs alongside the provision of expert medical oversight and monitoring. I feel extremely fortunate to have found them.
2) In your opinion, has being a patient at the Care Oncology Clinic been beneficial to you? If so, in what ways has it helped?
Yes. COC has provided me with access to safe, low toxicity, off-label drugs. The off-label drugs they prescribe all have a growing body of evidence to support their use against cancer, particularly in combination. I believe this drug protocol may provide me with a better chance of keeping my disease in remission. I am tolerating the drugs extremely well and am being actively monitored by the clinic every quarter. As part of the monitoring I get the opportunity to speak with highly qualified, open minded oncologists all of whom have excellent communication skills. This team are genuinely interested in thinking outside the box to assist patients who want to do more to prevent recurrence or to manage their disease. The data they are recording on treatment responses and different combinations could be incredibly meaningful for prolonging the lives of future patients.
3) What are your thoughts on the Care Oncology Clinic’s funding/joint venture initiatives to promote wider access to additional, evidence-based treatment?
The use of off-label drugs as part of a cancer treatment regime is very interesting and potentially very effective. I believe the promotion of the Care Oncology Clinic and they work they are doing is essential to progressing cancer treatment. Cocktail/combination therapy has proven highly effective in the management of several diseases through time (tuberculosis, HIV, leukaemia) and it’s about time that we had a committed and focused approach to using it for cancer. I sincerely hope the COC can raise the finances needed through their current campaign to continue this important work.
The collection of current patient data on off-label drugs for cancer in practice effectively becomes a “real world trial.” In addition, this data may help open the door for future patients in similar circumstances faster, rather than having to wait years for a double-blind randomised clinical trial to be conducted. There is no magic bullet for cancer and many cancer patients don’t want to wait for their disease to progress before taking greater action; I certainly didn’t. The question is – why wait to add in the COC drugs to your cancer treatment when it may potentially help whilst doing very little harm? It feels like a reasonable step to take when juxtaposed with doing nothing or rolling the dice on a clinical trial where you may end up with a placebo.
Here, we propose a new strategy for the treatment of early cancerous lesions and advanced metastatic disease, via the selective targeting of cancer stem cells (CSCs), a.k.a., tumor-initiating cells (TICs). We searched for a global phenotypic characteristic that was highly conserved among cancer stem cells, across multiple tumor types, to provide a mutation-independent approach to cancer therapy. This would allow us to target cancer stem cells, effectively treating cancer as a single disease of “stemness”, independently of the tumor tissue type. Using this approach, we identified a conserved phenotypic weak point – a strict dependence on mitochondrial biogenesis for the clonal expansion and survival of cancer stem cells. Interestingly, several classes of FDA-approved antibiotics inhibit mitochondrial biogenesis as a known “side-effect”, which could be harnessed instead as a “therapeutic effect”. Based on this analysis, we now show that 4-to-5 different classes of FDA-approved drugs can be used to eradicate cancer stem cells, in 12 different cancer cell lines, across 8 different tumor types (breast, DCIS, ovarian, prostate, lung, pancreatic, melanoma, and glioblastoma (brain)). These five classes of mitochondrially-targeted antibiotics include: the erythromycins, the tetracyclines, the glycylcyclines, an anti-parasitic drug, and chloramphenicol. Functional data are presented for one antibiotic in each drug class: azithromycin, doxycycline, tigecycline, pyrvinium pamoate, as well as chloramphenicol, as proof-of-concept. Importantly, many of these drugs are non-toxic for normal cells, likely reducing the side effects of anti-cancer therapy. Thus, we now propose to treat cancer like an infectious disease, by repurposing FDA-approved antibiotics for anti-cancer therapy, across multiple tumor types. These drug classes should also be considered for prevention studies, specifically focused on the prevention of tumor recurrence and distant metastasis. Finally, recent clinical trials with doxycycline and azithromycin (intended to target cancer-associated infections, but not cancer cells) have already shown positive therapeutic effects in cancer patients, although their ability to eradicate cancer stem cells was not yet appreciated.
Massachusetts General Hospital (MGH) investigators may have uncovered a novel mechanism behind the ability of the diabetes drug metformin to inhibit the progression of pancreatic cancer. In their report that has been published in the open access journal PLOS One, the research team describes finding that metformin decreases the inflammation and fibrosis characteristic of the most common form of pancreatic cancer. Their findings in cellular and animal models and in patient tumor samples also indicate that this beneficial effect may be most prevalent in overweight and obese patients.